Thrombosis and COVID-19

Last Week in Medicine

Contenu fourni par Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

4y ago 17:09

MP3•Maison d'episode

Today I do a quick review of the COVID-19 thrombosis literature from the last year to try to answer some of the following questions: Why does COVID-19 cause thrombosis? How many patients with COVID-19 develop thrombotic complications? Why do patients with COVID-19 on VTE prophylaxis still develop blood clots? Should we use intermediate dosing of anticoagulation for prophylaxis? What about full dose therapeutic anticoagulation (no!) What do the guidelines say?
Lots of papers:
JAMA IM Review
Autopsy Findings and VTE in Patients with COVID-19
Klok et al
Helms et al
Shah et al
Piazza et al
Porfidia et al
Kunutsor et al
Dutt et al
Stessel et al
Paranjpe et al
Fraisse et al
Musoke et al
Patel et al
ISTH Guidelines
ACCP Guidelines
Take home points:

COVID-19 is associated with an elevated risk of thrombosis.
Observational data suggests that ICU patients are likely to develop thrombotic complications even on standard VTE prophylaxis. This number seems to be round 25%. Ward patients are also at higher risk (around 8-9%).
Critically ill patients commonly develop heparin resistance, and this may partially explain why some patients with COVID develop thrombotic complications despite prophylaxis.
Some have suggested intermediate dosing of anticoagulation for prophylaxis, but there are no randomized controlled trials published at this time, and observational data are limited.
Some have suggested therapeutic dosing of anticoagulation for critically ill patients, but observational data show high rates of bleeding and other complications, and the three largest randomized controlled trials have stopped enrolling critically ill patients into the therapeutic anticoagulation arm due to safety concerns and futility.
Some have suggested targeting a certain anti-Xa activity level, but no one really knows what that should be, and there aren’t any guidelines recommending it.
ISTH and ACCP have both put out guidelines which are overall pretty similar.
Make sure your patient has VTE prophylaxis, preferably a LMWH, and keep an eye out for thrombotic complications so you can treat them in a timely manner.

Music from https://filmmusic.io
"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)
License: CC BY (http://creativecommons.org/licenses/by/4.0/)

58 episodes

#Fitness #Medicine #Stephen Jenkins, MD, Austin Rupp, MD #Austin Rupp #Internal Medicine #Medical Journals #Research Articles #Guidelines #Alternative Health #Mental Health